<DOC>
	<DOCNO>NCT01752855</DOCNO>
	<brief_summary>A Phase 2b , open-label extension ( OLE ) study rheumatoid arthritis ( RA ) patient design collect long-term safety , tolerability , efficacy , immunogenicity data propose new adalimumab formulation .</brief_summary>
	<brief_title>Study Rheumatoid Arthritis Subjects Who Completed Preceding Study M13-390 With Adalimumab</brief_title>
	<detailed_description>All participant complete Study NCT01712178 opportunity enroll study receive new adalimumab formulation dose 40 mg every week ( eow ) additional 24 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Subject complete precede Study M13390 rheumatoid arthritis develop discontinuation criterion study . 2 . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy and/or hysterectomy ) childbearing potential practicing approve method birth control throughout study 150 day last dose study drug . Examples approve method birth control include follow ( see local inform consent detail ) : Condoms , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) ; Hormonal contraceptives 90 day prior study drug administration ; A vasectomize partner . 3 . Subjects must able willing selfadminister subcutaneous ( SC ) injection qualify person available administer SC injection . 4 . Subject judge good general health determine Principal Investigator base upon result medical history , physical examination , laboratory profile perform Baseline . 5 . Subjects must able willing provide write informed consent comply requirement study protocol . 1 . Ongoing infection Week 0 NOT successfully treat . Subjects ongoing infection undergo treatment may enrol BUT NOT dose infection successfully treat . 2 . Subject currently use plan use antiretroviral therapy time study . 3 . Subject plan use live vaccine study . 4 . Positive pregnancy test Baseline ( Week 0 ) . 5 . Subject consider investigator , reason , unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>